Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.